Literature DB >> 8255773

Design and specificity of hammerhead ribozymes against calretinin mRNA.

J Ellis1, J Rogers.   

Abstract

We obtained a partial sequence of mouse calretinin mRNA from cDNA clones, and designed hammerhead ribozymes to cleave positions within it. With a view to optimising hammerhead ribozymes for eliminating the mRNA in vivo, we varied the length and sequence of the three duplex 'arms' and measured the cleavage of long RNA substrates in vitro at 37 degrees C (as well as 50 degrees C). Precise cleavage occurred, but it could only go to completion with a large excess of ribozyme. The evidence suggests that the rate-limiting step with a large target is not the cleavage, but the formation of the active ribozyme: substrate complex. The efficiency varied unpredictably according to the target site, the length of the substrate RNA, and the length of the ribozyme; secondary structure in vitro may be responsible. We particularly investigated the degree of sequence-specificity. Some mismatches could be tolerated, but shortening of the total basepairing with the substrate to less than 14 bp drastically reduced activity, implying that interaction with weakly-matched RNAs is unlikely to be a serious problem in vivo. These results suggest that specific and complete cleavage of a mRNA in vivo should be possible, given high-level expression of a ribozyme against a favourable target site.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255773      PMCID: PMC310633          DOI: 10.1093/nar/21.22.5171

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  42 in total

1.  CUUCGG hairpins: extraordinarily stable RNA secondary structures associated with various biochemical processes.

Authors:  C Tuerk; P Gauss; C Thermes; D R Groebe; M Gayle; N Guild; G Stormo; Y d'Aubenton-Carafa; O C Uhlenbeck; I Tinoco
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

2.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

3.  Design of RNA enzymes distinguishing a single base mutation in RNA.

Authors:  M Koizumi; Y Hayase; S Iwai; H Kamiya; H Inoue; E Ohtsuka
Journal:  Nucleic Acids Res       Date:  1989-09-12       Impact factor: 16.971

4.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

5.  Construction of a series of several self-cleaving RNA duplexes using synthetic 21-mers.

Authors:  M Koizumi; S Iwai; E Ohtsuka
Journal:  FEBS Lett       Date:  1988-02-15       Impact factor: 4.124

Review 6.  Self-cleavage of RNA in the replication of small pathogens of plants and animals.

Authors:  R H Symons
Journal:  Trends Biochem Sci       Date:  1989-11       Impact factor: 13.807

7.  Specific gene suppression by engineered ribozymes in monkey cells.

Authors:  F H Cameron; P A Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates.

Authors:  J F Milligan; D R Groebe; G W Witherell; O C Uhlenbeck
Journal:  Nucleic Acids Res       Date:  1987-11-11       Impact factor: 16.971

9.  Ribozyme mediated destruction of RNA in vivo.

Authors:  M Cotten; M L Birnstiel
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

10.  Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons.

Authors:  J H Rogers
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

View more
  14 in total

1.  Ribozyme-Spherical Nucleic Acids.

Authors:  Jessica L Rouge; Timothy L Sita; Liangliang Hao; Fotini M Kouri; William E Briley; Alexander H Stegh; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2015-08-14       Impact factor: 15.419

Review 2.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

3.  "Hairpin" and "hammerhead" ribozymes directed towards the mumps virus nucleocapsid RNA: specific cleavage of a small synthetic RNA substrate and full-length mRNA.

Authors:  J Albuquerque-Silva; M J De Vos; A Bollen; S Houard
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

4.  Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes.

Authors:  P Hendry; M McCall
Journal:  Nucleic Acids Res       Date:  1996-07-15       Impact factor: 16.971

5.  Strategies for the suppression of peroxidase gene expression in tobacco. I. Designing efficient ribozymes.

Authors:  C L McIntyre; J M Manners
Journal:  Transgenic Res       Date:  1996-07       Impact factor: 2.788

6.  Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.

Authors:  M Sioud
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

7.  Ribozyme-mediated RNA degradation in nuclei suspension.

Authors:  O Heidenreich; S H Kang; D A Brown; X Xu; P Swiderski; J J Rossi; F Eckstein; M Nerenberg
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

8.  Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.

Authors:  M Zoumadakis; M Tabler
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

9.  A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.

Authors:  M Tabler; M Homann; S Tzortzakaki; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

10.  tRNAVal-heterodimeric maxizymes with high potential as geneinactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells.

Authors:  T Kuwabara; M Warashina; A Nakayama; J Ohkawa; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.